Method of using a lead to regulate protein expression

• US 9,031,792 B2
• Filed: 03/27/2006
• Issued: 05/12/2015
• Est. Priority Date: 08/12/2005
• Status: Expired due to Fees

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Wagner, Darrell O., Sih, Haris J., Qu, Jihong, Ross, Jeffrey, Girouard, Steven D., Heil, Ronald W. Jr.
• Primary Examiner(s): Whaley, Pablo S
• Application Number:
  US11/277,552
• Publication Number:
  US 20070036771A1
• Time in Patent Office: 3,333 Days
• Field of Search: None
• US Class Current: 702/19
• CPC Class Codes: A61K 48/0008 characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
• CPC Class Codes: A61K 48/0083 characterised by an aspect of the administration regime
• CPC Class Codes: A61N 1/05 for implantation or insertion into the body, e.g. heart electrode A61N1/06 takes precedence
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A system and device are provided which include a gene regulatory system controlling expression of one or more expression cassettes present in or released by the device, by emitting one or more stimulations. An expression cassette includes a regulatable transcription control element that is responsive to the emitted stimulations linked to an open reading frame of interest. The system optionally includes a sensor to sense a parameter indicative of a need, a telemetry module to receive an external command, or a programmable device, for regulating gene expression of the open reading frame.

Claims

1. A method of using a lead to regulate expression of a soluble cellular protein, comprising:

a) providing a mammal implanted with i) a system comprising;

a lead including a lead body extending from a proximal end portion to a distal end portion;

one or more depositories disposed along and connected to the lead body, the one or more depositories include a porous, biocompatible and substantially nonbiodegradable material, wherein the material is selected to allow the passage of soluble protein expressed by donor cells and prevent passage of the donor cells across the material, wherein the porous, biocompatibie and substantially nonbiodegradable material comprises a synthetic polymer or a cross-linked natural polymer; and

one or more gene regulatory stimulators associated with the one or more depositories, the one or more gene regulatory stimulators emit light of a particular wavelength or light of a particular energy capable of regulating a regulatable transcription control element in an expression cassette including the regulatable transcription control element operably linked to an open reading frame of interest or in an endogenous gene which includes the regulatable transcription control element operably linked to an open reading frame of interest, wherein the open reading frame encodes the soluble protein,

wherein the one or more depositories comprise donor cells that are not genetically modified but comprise the regulatable transcription control element, donor cells that are genetically modified with the expression cassette, or a combination thereof, or

ii) a lead comprising;

a lead body extending from a proximal end portion to a distal end portion and having an intermediate portion therebetween;

one or more depositories disposed along and connected to the lead body, the one or more depositories include a porous, biocompatible and substantially nonbiodegradable material, wherein the material is selected to allow the passage of soluble protein expressed by donor cells and prevent passage of the donor cells across the material, wherein the porous, biocompatible and substantially nonbiodegradable material comprises a synthetic polymer or a cross-linked natural polymer;

the one or more depositories having donor cells that are genetically modified with an expression cassette comprising a regulatable transcription control element operably linked to an open reading frame of interest, donor cells which are not genetically modified but which comprise an endogenous gene which includes a regulatable transcription control element operably linked to an open reading frame of interest, or a combination thereof, wherein the open reading frame encodes the soluble protein; and

one or more gene regulatory stimulators associated with the one or more depositories, the one or more gene regulatory stimulators emit light of a particular wavelength or light of a particular energy capable of regulating the regulatable transcription control element; and

b) delivering the light from the one or more gene regulatory stimulators to the donor cells which are genetically modified or to the donor cells which are not genetically modified in the one or more depositories in an amount effective to regulate expression of the soluble protein.

2. The method of claim 1, wherein the delivery of the regulatory stimulation is in response to a sensed physiological parameter in the mammal.

3. The method of claim 2, wherein the physiological parameter is sensed by an implanted sensor.

4. The method of claim 1, wherein the delivery of the regulatory stimulation is in response to a command.

5. The method of claim 4, wherein the command is an external command.

6. The method of claim 4, wherein the command is from an implanted programmable device.

7. The method of claim 1, further comprising ceasing delivery of the regulatory stimulation.

8. The method of claim 7, wherein the delivery ceases in response to receiving a command.

9. The method of claim 8, wherein the command is an external command.

10. The method of claim 8, wherein the command is from an implanted programmable device.

11. The method of claim 5 or 9, wherein the external command is entered by at least one of physician or other caregiver, or a patient through an external system.

12. The method of claim 1, wherein the delivery of the regulatory stimulation is in response to a sensed physiological parameter indicative of ischemia, remodeling or myocardial infarction in the mammal.

13. The method of claim 12, wherein the regulatory stimulation is in response to a sensed physiological parameter indicative of ischemia and is delivered in response to a sensed S-T segment deviation from baseline, prolongation of the Q-T interval, T-wave inversion, shortness of breath, chest pain, blood pH of less than 7.0, blood K⁺ concentration of greater than 10 mM, glucose concentration of less than about 80 mg/dl or greater than about 115 mg/dl, or oxygen concentration of less than about 90% pO₂.

14. The method of claim 12, wherein the regulatory stimulation is in response to a sensed physiological parameter indicative of remodeling and is delivered in response to a sensed decrease in ejection fraction or QRS complex width of greater than about 120 msec.

15. The method of claim 1, wherein the regulatory stimulation is in response to a sensed physiological parameter indicative of myocardial infarction and delivered in response to a sensed aberrant electrical activation front, S-T segment elevation, Q wave alteration, reduced R wave amplitude, chest pain or shortness of breath.

16. The method of claim 1, wherein the regulation of the expression prevents, inhibits or treats cardiac ischernia, cardiac remodeling or myocardial infarction in the mammal.

17. The method of claim 1, wherein the regulation of the expression enhances preconditioning of the heart for ischemia, repair of infarcted myocardial tissue, or reverse remodeling in the mammal.

18. The method of claim 1, wherein the delivery of the regulatory stimulation is in response to a sensed worsening of heart failure, atrial fibrillation, ventricular fibrillation, ventricular tachycardia, or bradycardia in the mammal.

19. The method of claim 1, further comprising transmitting light energy from a source via a fiber optic wave guide of the lead.

20. The method of claim 1, further comprising placing the lead within an external energy field.

21. The method of claim 1 wherein the material comprises ethylene vinyl acetate copolymer (EVA), polymethyl methacrylate, polyamides, polycarbonates, polyesters, polyethylene, polypropylenes, polystyrenes, polyvinyl chloride, polytetrafluoroethylene, N-isopropylacrylamide copolymers, poly(ethylene oxide)/poly(propylene oxide) block copolymers, poly(ethylene glycol)/poly(D,L-lactide-co-glycolide) block copolymers, polyglycolide, polylactides (PHA or PDLA), poly(caprolactone) (PCL), poly(dioxanone) (PPS), cellulose or cellulose acetate.